All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study
David R. Nelson(Harvard University Press), Khurram Rana(Inova Fairfax Hospital), Eric Hughes(The University of Texas at San Antonio Health Science Center), Delphine Hennicken(Inova Fairfax Hospital), Norman Gitlin(NYU Langone Health), Ziad Younes(American College of Veterinary Surgeons), Aasim Sheikh(GI Specialists of Georgia (United States)), Trevor Hawkins(University of Florida), Michael Bennett(Associates Research), Paul J. Pockros(Scripps Clinic), Paul J. Thuluvath(University of Maryland, Baltimore), Bradley Freilich(Kansas City Research Institute), Godson Oguchi(University of Florida), Eric Lawitz(The University of Texas at San Antonio Health Science Center), Peter Varunok(Inova Fairfax Hospital), Grisell Ortiz‐Lasanta(University of Florida), Natarajan Ravendhran(University of Florida), Mordechai Rabinovitz(The University of Texas at San Antonio Health Science Center), Reem Ghalib(Clinical Research Institute), Fiona McPhee(Bristol-Myers Squibb (United States)), Kris V. Kowdley(Liver Institute Northwest), James N. Cooper(Inova Fairfax Hospital), David Bernstein(University of Florida), Jacob Lalezari(Quest Clinical Research (United States)), William R. Harlan(Asheville Cardiology Associates)
Cited by 689
Related Papers
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k